Overview of breast cancer therapy
TA Moo, R Sanford, C Dang, M Morrow - PET clinics, 2018 - pet.theclinics.com
The diagnosis and treatment of invasive breast cancer requires a collaborative effort among
multiple subspecialties. Diagnostic imaging workup and biopsy play a key role in …
multiple subspecialties. Diagnostic imaging workup and biopsy play a key role in …
Biology and management of patients with triple-negative breast cancer
P Sharma - The oncologist, 2016 - academic.oup.com
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …
associated with poor long-term outcomes compared with other breast cancer subtypes …
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early …
R Gray, R Bradley, J Braybrooke, Z Liu, R Peto… - The lancet, 2019 - thelancet.com
Background Increasing the dose intensity of cytotoxic therapy by shortening the intervals
between cycles, or by giving individual drugs sequentially at full dose rather than in lower …
between cycles, or by giving individual drugs sequentially at full dose rather than in lower …
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 …
J Braybrooke, R Bradley, R Gray, RK Hills, H Pan… - The Lancet, 2023 - thelancet.com
Background Anthracycline–taxane chemotherapy for early-stage breast cancer substantially
improves survival compared with no chemotherapy. However, concerns about short-term …
improves survival compared with no chemotherapy. However, concerns about short-term …
Anthracyclines in early breast cancer: The abc trials—usor 06-090, nsabp b-46-i/usor 07132, and nsabp b-49 (nrg oncology)
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and
cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to …
cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to …
Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0
SM Tolaney, E Garrett-Mayer, J White… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria,
established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial …
established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial …
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study
I Vaz-Luis, RA Ottesen, ME Hughes… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Treatment decisions for patients with T1a, bN0M0 breast cancer are challenging.
We studied the time trends in use of adjuvant chemotherapy and survival outcomes among …
We studied the time trends in use of adjuvant chemotherapy and survival outcomes among …
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2× 2 factorial, randomised phase 3 trial
L Del Mastro, S De Placido, P Bruzzi, M De Laurentiis… - The Lancet, 2015 - thelancet.com
Background Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel
(EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is …
(EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is …
[HTML][HTML] Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer
Materials and methods: With this purpose, a descriptive cross-sectional study was
developed on 110 breast cancer patients who were treated with docetaxel, epirubicin, and …
developed on 110 breast cancer patients who were treated with docetaxel, epirubicin, and …
[HTML][HTML] Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast …
A Schneeweiss, V Möbus, H Tesch, C Hanusch… - European journal of …, 2019 - Elsevier
Background GeparOcto compared efficacy and safety of two chemotherapy regimens in high-
risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin …
risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin …